About Tezcat Biosciences:
Tezcat Biosciences is developing a RAS Therapeutic Discovery Platform to unlock the full potential of druggable targets. Tezcat combines validated discovery tools and their proprietary enabling technology to create new therapies. The Discovery Platform is scalable, as it can be applied to context-dependent iterations and various indications to support both internal R&D and strategic partnerships.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. Tezcat Biosciences has participated in the following programs:
Tezcat Biosciences is developing a RAS Therapeutic Discovery Platform to unlock the full potential of druggable targets. Tezcat combines validated discovery tools and their proprietary enabling technology to create new therapies. The Discovery Platform is scalable, as it can be applied to context-dependent iterations and various indications to support both internal R&D and strategic partnerships.
Born out of NYU Langone Health, our team is committed to refining and delivering the leading-edge technology from bench to bedside. Tezcat Biosciences has participated in the following programs:
- 2021 TMC Accelerator for Cancer Therapeutics, part of TMC Innovation and funded by Cancer Prevention and Research Institute of Texas (CPRIT)
- 2020 JLABs Virtual Program, part of Johnson & Johnson Innovation
- 2018 Entrepreneurship Lab (ELab) Program, an initiative of NYC's Economic Development Corporation (NYCEDC).